Watch for
Claims and labels worth a closer look
Check the product, the person and the follow-up plan before paying. Keep the exact names in front of you.
Check the claim before the offer
MythThe words “FDA registered” prove the medicine has FDA approval.
The fact
FDA means Food and Drug Administration.
Compounding is making a custom medicine.
As checked on September 26, 2026, the words “FDA registered” are no proof that the FDA has approved a medicine or business.
A prescription medicine offered without a prescription
Giving someone a prescription-only drug without a valid prescription violates federal law, as of September 26, 2026.
Ask who assesses you and writes the prescription.
A research label presented as treatment
The FDA warns against weight-drug products with research labels that are offered for people to use; their quality is unknown, as of September 26, 2026.
They may harm people who use them.
Federal law does not allow compounding with retatrutide or cagrilintide, according to the FDA as of September 26, 2026.
A custom product described as the same as an approved drug
The FDA regards it as misleading to call a compounded drug a generic or claim it is identical to an approved drug, as of September 26, 2026.
An approved copy of a brand drug is called a generic; compounding uses a different process.
A pharmacy name that cannot be confirmed
Some labels for compounded tirzepatide and semaglutide carry false pharmacy names, according to FDA reports as of September 26, 2026.
Ask the pharmacy itself to confirm it supplied the medicine. Use the pharmacy-board link in further reading to check its permit.
No way to ask about a confusing label
The FDA has reports of measuring errors with compounded semaglutide; some involved hospital care, as of September 26, 2026.
Ask the person writing your prescription or the pharmacist to explain unclear instructions.
Avoid guessing or using a website calculator to work out how much medicine to use.
Check the arrival and storage instructions
Check cooling for these injections
The FDA advises against using semaglutide or tirzepatide injections that arrive warm or lack proper cooling, as of September 17, 2026.
Contact the pharmacy and the person who wrote the prescription about an arrival problem.
Use the instructions for the exact product
Storage needs differ between peptide medicines; some need cooling and some are kept at room temperature.
Have the pharmacy walk you through your label’s directions for storing the medicine.